RhumbLine Advisers’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

RhumbLine Advisers’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-19,794	Closed	-$46K	–	3049
2019 Q1	$46K	Buy	19,794 +417	+2%	+$1.13K	﹤0.01%	2923
2018 Q4	$45K	Buy	19,377 +6,702	+53%	+$59.1K	﹤0.01%	2949
2018 Q3	$188K	Sell	12,675 -1,000	-7%	-$15.9K	﹤0.01%	2748
2018 Q2	$208K	Buy	13,675 +1,812	+15%	+$30.8K	﹤0.01%	2720
2018 Q1	$223K	Buy	+11,863	New	+$207K	﹤0.01%	2564

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RhumbLine Advisers's SNNA Position: Q2 2019 in Review

RhumbLine Advisers sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q2 2019, closing a stake of 19,794 shares — an estimated $46K sold.

RhumbLine Advisers first reported a position in SNNA in Q1 2018 and held it in 5 quarters. The position peaked at $223K in Q1 2018. 48 funds tracked by Wall St. Rank hold SNNA as of Q2 2019.

RhumbLine Advisers reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
RhumbLine Advisers sold 19,794 Sienna Biopharmaceuticals, Inc. shares in Q2 2019, an estimated $46K.
RhumbLine Advisers first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2018 and held it in 5 quarters.
RhumbLine Advisers's Sienna Biopharmaceuticals, Inc. position peaked at $223K in Q1 2018.
48 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q2 2019.

Based on RhumbLine Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.